Dogwood Therapeutics reported a net loss of $21.4 million for the nine months ended September 30, 2026, which included a $9.2 million impairment charge related to IPR&D. The company ended the period with $4.9 million in cash and cash equivalents, down from $6.5 million at the end of 2025.
Dogwood Therapeutics reported third quarter 2026 financial results, highlighting the completion of its Halneuron Phase 2b trial for chemotherapy-induced neuropathic pain with top-line results expected in November 2026. The company also closed a $5 million private placement with Sealbond Limited to fund Phase 3 preparatory activities, extending its cash runway into the first quarter of 2027.
Term
3 months
“With results from the recently completed Phase 2b CINP study to be reported in November, we believe that if successful, Halneuron® could represent the first new therapeutic agent for millions of CINP patients in the US and tens of millions of CINP patients across the globe.”
Greg Duncan, Chief Executive Officer of Dogwood Therapeutics
Dogwood Therapeutics entered into a subscription agreement to sell 4,098,360 shares of common stock to its largest shareholder, Sealbond Limited (a subsidiary of CK Life Sciences), in a $5 million private placement. The proceeds will be used to fund Phase 3 preparatory activities for Halneuron® and extend the company's operational runway through March 2027.